Campbell Rogers Sells 64,533 Shares of Heartflow (NASDAQ:HTFL) Stock

Heartflow, Inc. (NASDAQ:HTFL) insider Campbell Rogers sold 64,533 shares of the business’s stock in a transaction that occurred on Thursday, March 19th. The stock was sold at an average price of $25.69, for a total value of $1,657,852.77. Following the transaction, the insider owned 78,518 shares in the company, valued at $2,017,127.42. The trade was a 45.11% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Campbell Rogers also recently made the following trade(s):

• On Thursday, February 12th, Campbell Rogers sold 65,153 shares of Heartflow stock. The shares were sold at an average price of $24.49, for a total value of $1,595,596.97.

Heartflow Stock Up 3.1%

Shares of Heartflow stock traded up $0.80 during trading on Monday, reaching $26.82. The company’s stock had a trading volume of 2,217,199 shares, compared to its average volume of 1,458,576. The business has a 50 day moving average price of $26.76 and a 200-day moving average price of $30.35. Heartflow, Inc. has a 12-month low of $20.13 and a 12-month high of $41.22.

Hedge Funds Weigh In On Heartflow

Several hedge funds have recently bought and sold shares of the stock. Baillie Gifford & Co. purchased a new stake in shares of Heartflow in the third quarter valued at $101,182,000. TD Asset Management Inc purchased a new stake in Heartflow during the 3rd quarter worth about $2,692,000. New York State Common Retirement Fund acquired a new position in Heartflow in the 3rd quarter valued at about $4,015,000. Fred Alger Management LLC acquired a new position in Heartflow in the 3rd quarter valued at about $9,997,000. Finally, Artisan Partners Limited Partnership purchased a new position in Heartflow in the 3rd quarter valued at about $16,817,000.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the stock. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Heartflow in a research note on Monday, December 29th. Wells Fargo & Company decreased their price objective on shares of Heartflow from $38.00 to $35.00 and set an “overweight” rating on the stock in a report on Thursday. Canaccord Genuity Group increased their target price on shares of Heartflow from $40.00 to $43.00 and gave the company a “buy” rating in a report on Thursday. Finally, JPMorgan Chase & Co. decreased their price target on Heartflow from $40.00 to $35.00 and set an “overweight” rating on the stock in a research note on Thursday. Five research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $37.67.

Heartflow Company Profile

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.